InMed Pharmaceuticals (INM) Operating Income: 2022-2025
Historic Operating Income for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.8 million.
- InMed Pharmaceuticals' Operating Income fell 4.94% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 10.66%. This contributed to the annual value of -$7.9 million for FY2025, which is 3.05% up from last year.
- Latest data reveals that InMed Pharmaceuticals reported Operating Income of -$1.8 million as of Q3 2025, which was down 0.04% from -$1.8 million recorded in Q2 2025.
- InMed Pharmaceuticals' 5-year Operating Income high stood at -$485,150 for Q2 2023, and its period low was -$6.5 million during Q2 2022.
- Moreover, its 3-year median value for Operating Income was -$1.8 million (2024), whereas its average is -$1.9 million.
- Per our database at Business Quant, InMed Pharmaceuticals' Operating Income skyrocketed by 92.56% in 2023 and then slumped by 319.30% in 2024.
- Quarterly analysis of 4 years shows InMed Pharmaceuticals' Operating Income stood at -$2.2 million in 2022, then climbed by 25.70% to -$1.6 million in 2023, then tumbled by 37.03% to -$2.3 million in 2024, then declined by 4.94% to -$1.8 million in 2025.
- Its Operating Income was -$1.8 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$2.1 million in Q1 2025.